Neuroendocrine effects of Citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans

Berardelli, Rita; Margarito, Enrica; Ghiggia, Federica; Picu, Andreea; Balbo, M.; Bonelli, Lorenza; Giordano, Roberta; Karamouzis, Ioannis; Bo, Mario; Ghigo, Ezio; Arvat, Emanuela

doi:10.1007/bf03346666

Cited by 6 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No effect of age on cortisol response in men 236 c. Selective serotonin reuptake inhibitor (citalopram) i. ↑ ACTH secretion with age in men 237 4. Sex-steroid interactions a.…”

Section: Similar Changes Occur In Aging As In Hpa Hyperactivitymentioning

confidence: 99%

Age-Dependent and Gender-Dependent Regulation of Hypothalamic-Adrenocorticotropic-Adrenal Axis

Veldhuis

Sharma

Roelfsema

2013

Endocrinology and Metabolism Clinics of North America

View full text Add to dashboard Cite

“…No effect of age on cortisol response in men 236 c. Selective serotonin reuptake inhibitor (citalopram) i. ↑ ACTH secretion with age in men 237 4. Sex-steroid interactions a.…”

Section: Similar Changes Occur In Aging As In Hpa Hyperactivitymentioning

confidence: 99%

Age-Dependent and Gender-Dependent Regulation of Hypothalamic-Adrenocorticotropic-Adrenal Axis

Veldhuis

Sharma

Roelfsema

2013

Endocrinology and Metabolism Clinics of North America

View full text Add to dashboard Cite

“…Several studies have examined changes in peripheral endogenous DHEA(S) levels over the course of antidepressant treatment (Berardelli et al, 2010; Deuschle et al, 2004; Fabian et al, 2001; Hsiao, 2006; Markopoulou et al, 2009; Morgan et al, 2010; Morita et al, 2014; Paslakis et al, 2010; Romeo et al, 1998; Schüle et al, 2009; Takebayashi et al, 1998; Zhu et al, 2015) and in relation to treatment response (Deuschle et al, 2004; Fabian et al, 2001; Hsiao, 2006; Markopoulou et al, 2009; Morita et al, 2014; Paslakis et al, 2010; Schüle et al, 2009; Takebayashi et al, 1998). However, to the best of our knowledge, only three previous studies have examined peripheral endogenous DHEA or DHEA-S levels in MDD in relation to clinical response/remission after pharmacological treatment (Fabian et al, 2001; Hsiao, 2006; Markopoulou et al, 2009), and none has examined response to selective serotonin reuptake inhibitors (SSRIs) specifically.…”

Section: Introductionmentioning

confidence: 99%

Higher serum DHEA concentrations before and after SSRI treatment are associated with remission of major depression

Hough

Lindqvist

Epel

et al. 2017

Psychoneuroendocrinology

View full text Add to dashboard Cite

Background Dehydroepiandrosterone (DHEA) and its sulfated ester DHEA-sulfate (DHEA-S), (together DHEA[S]), are the most abundant adrenal steroids in humans and are found in blood and the brain, where they function as neurosteroids with direct receptor affinities. Preclinical studies suggest that DHEA(S) has antidepressant/neuroprotective properties, and exogenously administered DHEA has shown antidepressant efficacy in humans. Nonetheless, the role of endogenous DHEA(S) levels in major depressive disorder (MDD) and antidepressant outcomes remains unclear. Methods Morning fasting serum DHEA(S) concentrations were determined in 36 healthy, unmedicated MDD adults with Hamilton Depression (HDRS) ratings ≥17, and 75 healthy controls. MDD participants then completed eight weeks of open-label SSRI treatment before DHEA(S) levels were re-sampled; those with post-treatment HDRS ratings ≤7 were classified as “Remitters.” Pre- and post-treatment DHEA(S) levels of Remitters and Non-remitters were compared, controlling for age, sex, and BMI. Results Pre-treatment HDRS ratings did not differ between Remitters and Non-remitters (p=0.179). Baseline DHEA levels of Remitters were significantly higher than both Non-remitters (p=0.008) and controls (p=0.004); baseline DHEA-S levels of Remitters were also higher than Non-remitters (p=0.040) but did not significantly differ from controls (p=0.096). Non-remitters did not significantly differ from controls. Post-treatment DHEA(S) levels remained higher in Remitters compared to Non-remitters (DHEA: p=0.013; DHEA-S: p=0.040). Conclusions These data suggest that higher circulating DHEA(S) levels (while unmedicated and after eight weeks of SSRI treatment) predict SSRI-associated remission in MDD. This raises the possibility that endogenous DHEA(S) abundance is a physiological adjunct to SSRI efficacy, as suggested by prior preclinical and clinical studies.

show abstract

Pituitary side effects of old and new drugs

Zatelli

Ambrosio

Bondanelli

et al. 2014

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

Neuroendocrine effects of Citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans

Abstract: Corticotrope response to CT is age-dependent in normal men, being amplified starting from middle age, suggesting precocious changes in the serotonergic neuroendocrine control during lifespan. CT is a useful tool to evaluate the age-dependent serotonergic function in humans.

Cited by 6 publications

References 48 publications

Age-Dependent and Gender-Dependent Regulation of Hypothalamic-Adrenocorticotropic-Adrenal Axis

Age-Dependent and Gender-Dependent Regulation of Hypothalamic-Adrenocorticotropic-Adrenal Axis

Higher serum DHEA concentrations before and after SSRI treatment are associated with remission of major depression

Pituitary side effects of old and new drugs

Contact Info

Product

Resources

About